20000575271

PCT WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 6 : C12N 9/00 — A2

(11) International Publication Number: **WO 99/55847**

(43) International Publication Date: 4 November 1999 (04.11.99)

(21) International Application Number: PCT/US99/09027

(22) International Filing Date: 26 April 1999 (26.04.99)

(30) Priority Data:

60/083,217	27 April 1998 (27.04.98)	US
60/100,842	18 September 1998 (18.09.98)	US
09/257,608	25 February 1999 (25.02.99)	US
09/274,553	23 March 1999 (23.03.99)	US

(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).

Published
Without international search report and to be republished upon receipt of that report.

(71) Applicant *(for all designated States except US)*: RIBOZYME PHARMACEUTICALS, INC. [US/US]; 2950 Wilderness Place, Boulder, CO 80301–5411 (US).

(72) Inventors; and

(75) Inventors/Applicants *(for US only)*: BLATT, Lawrence [US/US]; 2176 Riverside Lane, Boulder, CO 80304 (US). MCSWIGGEN, James, A. [US/US]; 4866 Franklin Drive, Boulder, CO 80301 (US). ROBERTS, Elisabeth [US/US]; 10025 Eliot Circle, Federal Heights, CO 80221 (US). PAVCO, Pamela, A. [US/US]; 705 Barberry Circle, Lafayette, CO 80026 (US). MACEJAK, Dennis [US/US]; 6595 Union Street, Arvada, CO 80004 (US).

(74) Agent: AMES, Wesley, B.; Lyon & Lyon LLP, Suite 4700, 633 West Fifth Street, Los Angeles, CA 90071–2066 (US).

(54) Title: ENZYMATIC NUCLEIC ACID TREATMENT OF DISEASES OR CONDITIONS RELATED TO HEPATITIS C VIRUS INFECTION

(57) Abstract

Enzymatic nucleic acid molecules which modulate the expression and/or replication of hepatitis C.

